ClinicalTrials.gg
CompletedNCT01450319MUTEXUpdated Nov 28, 2016Results posted

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

A Phase 2 interventional study of Cetuximab in Colorectal Neoplasms, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 9 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
86th of 185
73 · median 60
Started
2011
with 3 others
Phase 2
107 of 187
20 open now
Registered
93rd of 187
by date
Lead sponsor
4 of 187
Merck KGaA, Darmstadt, Germany

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 86th largest by enrollment of the 185 interventional ones that give a count, is one of 4 that started in 2011, is one of 107 in phase 2, and was the 93rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa polymorphism tumors, in which there is no therapeutic alternative for treatment. Failure of the first and second line conventional therapeutic lines was documented.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • K-RAS
  • FcγRII/IIIa genotypes
  • CRC
  • Colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written form signed by the subject
  • Age greater than or equal to (>=) 18 years
  • (ECOG) performance status less than or equal to (=\<) 2
  • of greater than (>) 2 months
  • Histological confirmed colorectal cancer (CRC) with mutated K-RAS and favorable genotypes (any H in FcγRIIa-131). Selection will be done only based on Cluster of differentiation (CD)32 polymorphisms
  • Epidermal growth factor receptor (EGFR) expression in his/her tumor sample
  • Stage 4 disease, with at least 1 according to version 1.1 (RECIST v1.1) criteria, documented within 28 days prior to the study inclusion
  • Tumor tissue sample available for the assessment of K-RAS status and FcγRIIa (CD32) genotype
  • Subject who has received at least 2 prior therapeutic lines
  • Adequate bone marrow function, defined as:

    • > 9.0 gram per deciliter (g/dL)
    • count >100*10\^9 per liter
    • (ANC) >=1.5*10\^9/Liter
  • Adequate hepatic and renal function, defined as:

    • Serum =\<1.5 times the (ULN)
    • (ALT) and aspartate aminotransferase (AST) =\<2.5*ULN in absence of liver metastasis and ALT and AST =\<5*ULN in the presence of liver metastasis
    • Alkaline phosphatase =\<2.5*ULN or =\<5 in the presence of liver metastasis or =\<10 in the absence of liver metastasis
    • >= 50 milliliter per minute (mL/min) (according to Cockcroft and Gault formula) or serum creatinine \<1.5*ULN
  • Adequate recovery after recent surgery, chemotherapy or radiotherapy. Prior major surgery, chemotherapy, treatment with an product or radiotherapy must have occurred at least 4 weeks before study inclusion
  • Women of must have a negative pregnancy test performed within 7 days prior to the study inclusion. women must be amenorrheic for at least 12 months. If the risk of conception exists both male and female subjects must use effective (for example, abstinence, intrauterine device (IUD), oral contraceptive, double barrier method or to be surgically sterile) since the signature of the consent form until at least 6 months after the end of treatment or end of last dose, whichever occurs first

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with monoclonal antibodies against EGFR
  • Toxicity, due to previous treatment, not resolved to Grade 1 before the subject's inclusion into the study
  • coronary disease or myocardial infarction, unstable angina, Grade >=2 congestive cardiac insufficiency according to (NYHA) within 6 months before starting the study treatment
  • Clinically significant vascular disease (for example, aortic aneurysm which requires surgery, pulmonary embolism, recent peripheral arterial thrombosis) within 12 months prior to starting the study treatment
  • Evidence of uncontrolled
  • History of active neurological disease
  • History of uncontrolled seizures
  • History of lung fibrosis, acute pulmonary damage or interstitial pneumonia
  • Known (HIV) infection or chronic or C infection, or presence of severe, uncontrolled intercurrent infections or other severe uncontrolled concomitant diseases
  • Current Grade >=2 (National Cancer Institute [NCI-CTCAE]) infection
  • History of uncontrolled diabetes, uncontrolled hypertension or hepatic involvement
  • Known or suspected allergy or to cetuximab
  • History of previous other than CRC occurring within 5 years before starting the study treatment, except for previously cured basal cell carcinoma of skin or carcinoma in situ of the cervix or urinary bladder treated more than 2 years before recruitment
  • Participation in another treatment study with an drug within the last 30 days
  • Pregnancy or lactation
  • Any medical, psychological, psychiatric or social uncontrolled problem which may interfere in the participation of the subject in the study or in the evaluation of the study results
  • Psychological, familiar or geographic conditions not allowing the adequate follow-up and adherence to the study protocol
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Cetuximab

    Drug: Cetuximab

Interventions

  • Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.

    Also known as: Erbitux

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) Time

    Overall survival was defined as the time from date of informed consent signature until death.

    Time frame: From the date of informed consent signature until death, assessed up to 3 years

Secondary outcomes

  1. Percentage of Subjects With Disease Control Rate (DCR)

    DCR was defined as those subjects achieving complete response (CR), partial response (PR) or stable disease (SD), according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the sum of longest diameter (SLD) of the TLs, taking as a reference the baseline (BL) SLD; Stable disease (SD) was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For non-target lesions (NTLs), CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and progressive disease (PD) was defined as the appearance

    Time frame: From the date of informed consent signature until progressive disease, assessed up to 3 years

  2. Progression Free Survival (PFS) Time

    PFS was defined as the time from informed consent signature until PD or death, whatever occurred first. Subjects who did not have disease progression or were lost to follow-up, were censored at the date of last contact, known to be alive and progression free; moreover, those subjects who started a new treatment (different from cetuximab), were censored at the date of starting the new treatment. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from BL or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.

    Time frame: From the date of informed consent signature until progressive disease (PD) or death, assessed up to 3 years

  3. Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, AEs Leading to Death

    An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the date of enrollment up to 30 days after the last dose of study drug administration, assessed up to 3 years

  4. Number of Subjects With Fcγ Receptors (FCγR) IIa/IIIa Polymorphisms

    The antibody fragment C portion (FCy) of cetuximab interacts with Fc-gamma receptors (FCyRs) expressed by immune effector cells. Polymorphisms were described in genes coding for FCyRIIa and in FCyRIIIa. A histidine/arginine polymorphism at position 131 for FCyRIIa gene and valine ⁄ phenylalanine polymorphism at position 158 for the FCyRIIIa gene were reported to be functionally relevant in the ADCC mechanism. All subjects were analyzed and classified as carriers of every different polymorphism of FCy Receptors: for FCyRIIa (H/H, homozygous alleles with histidine and R/H, heterozygous alleles with arginine/histidine) and FCyRIIIa (V/V, homozygous alleles with valine, F/F, homozygous alleles with phenylalanine and F/V, heterozygous alleles with valine ⁄ phenylalanine) (units: subjects with every type of polymorphism) .The FCyR genotype was determined using a TaqMan Allelic Discrimination Assay.

    Time frame: Baseline

  5. Overall Survival (OS) Related to Codon G13D

    OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).

    Time frame: From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal up to 3 years)

  6. Overall Survival (OS) Related to Killer Inhibitory Receptors 2DS4 (KIR2DS4) Functional Receptor (f/d) and Non-functional Receptor (NFR)

    OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).

    Time frame: From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal assessed up to 3 years)

  7. Beta 2-microglobulin

    Time frame: Baseline, Week 8

07

Results

Posted Jun 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneCetuximab
Started70
Completed70
Not completed0

Outcome measures

PrimaryOverall Survival (OS) Time

Overall survival was defined as the time from date of informed consent signature until death.

Time frame:
From the date of informed consent signature until death, assessed up to 3 years
Reported as:
Median · Months
Overall Survival (OS) Time
MonthsCetuximab
Overall Survival (OS) Time6.71 (5.42 to 8.05)
SecondaryPercentage of Subjects With Disease Control Rate (DCR)

DCR was defined as those subjects achieving complete response (CR), partial response (PR) or stable disease (SD), according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30 percent (%) decrease in the sum of longest diameter (SLD) of the TLs, taking as a reference the baseline (BL) SLD; Stable disease (SD) was defined as neither sufficient decrease in SLD to qualify for PR nor sufficient increase in SLD to qualify for PD; and PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started. For non-target lesions (NTLs), CR was defined as the disappearance of all NTLs and normalization of tumor marker levels; SD was defined as the persistence of 1 or more NTLs and/or maintenance of tumor marker levels above normal limits; and progressive disease (PD) was defined as the appearance

Time frame:
From the date of informed consent signature until progressive disease, assessed up to 3 years
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Disease Control Rate (DCR)
Percentage of subjectsCetuximab
Percentage of Subjects With Disease Control Rate (DCR)22.86
SecondaryProgression Free Survival (PFS) Time

PFS was defined as the time from informed consent signature until PD or death, whatever occurred first. Subjects who did not have disease progression or were lost to follow-up, were censored at the date of last contact, known to be alive and progression free; moreover, those subjects who started a new treatment (different from cetuximab), were censored at the date of starting the new treatment. For TLs, PD was defined at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from BL or the appearance of one or more new lesions. For NTLs, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing NTLs. Participants without second-line PD or death were censored at the date of last tumor assessment where non-progression was documented.

Time frame:
From the date of informed consent signature until progressive disease (PD) or death, assessed up to 3 years
Reported as:
Median · Months
Progression Free Survival (PFS) Time
MonthsCetuximab
Progression Free Survival (PFS) Time2.53 (2.43 to 2.70)
SecondaryNumber of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, AEs Leading to Death

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From the date of enrollment up to 30 days after the last dose of study drug administration, assessed up to 3 years
Reported as:
Number · Subjects
Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, AEs Leading to Death
SubjectsCetuximab
AEs69
SAEs17
AEs leading to discontinuation2
AEs leading to death3
SecondaryNumber of Subjects With Fcγ Receptors (FCγR) IIa/IIIa Polymorphisms

The antibody fragment C portion (FCy) of cetuximab interacts with Fc-gamma receptors (FCyRs) expressed by immune effector cells. Polymorphisms were described in genes coding for FCyRIIa and in FCyRIIIa. A histidine/arginine polymorphism at position 131 for FCyRIIa gene and valine ⁄ phenylalanine polymorphism at position 158 for the FCyRIIIa gene were reported to be functionally relevant in the ADCC mechanism. All subjects were analyzed and classified as carriers of every different polymorphism of FCy Receptors: for FCyRIIa (H/H, homozygous alleles with histidine and R/H, heterozygous alleles with arginine/histidine) and FCyRIIIa (V/V, homozygous alleles with valine, F/F, homozygous alleles with phenylalanine and F/V, heterozygous alleles with valine ⁄ phenylalanine) (units: subjects with every type of polymorphism) .The FCyR genotype was determined using a TaqMan Allelic Discrimination Assay.

Time frame:
Baseline
Reported as:
Number · Subjects
Number of Subjects With Fcγ Receptors (FCγR) IIa/IIIa Polymorphisms
SubjectsCetuximab
FcγRIIa: H/H27
FcγRIIa: R/H43
FcγRIIIa: V/V6
FcγRIIIa: F/F28
FcγRIIIa: F/V36
SecondaryOverall Survival (OS) Related to Codon G13D

OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).

Time frame:
From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal up to 3 years)
Reported as:
Median · months
Overall Survival (OS) Related to Codon G13D
monthsCetuximab
G13D (n=14)7.2 (4.8 to NA)
No G13D (n=48)6.3 (4.8 to 7.9)
SecondaryOverall Survival (OS) Related to Killer Inhibitory Receptors 2DS4 (KIR2DS4) Functional Receptor (f/d) and Non-functional Receptor (NFR)

OS was defined as the time from informed consent signature until death. Subjects without death were censored at the last date known alive (within the study).

Time frame:
From the date of informed consent signature until death, lost-to-follow-up or end of study, whatever occurred first (maximal assessed up to 3 years)
Reported as:
Median · months
Overall Survival (OS) Related to Killer Inhibitory Receptors 2DS4 (KIR2DS4) Functional Receptor (f/d) and Non-functional Receptor (NFR)
monthsCetuximab
f/d (n=10)4.8 (2.2 to 7.3)
NFR (n=56)7.4 (6.0 to 8.4)
SecondaryBeta 2-microglobulin
Time frame:
Baseline, Week 8
Reported as:
Mean · microgram per milliliter (mcg/mL)
Beta 2-microglobulin
microgram per milliliter (mcg/mL)Cetuximab
Baseline (n=61)2.35 ± 0.58
Week 8 (n=29)2.37 ± 1.13

Adverse events

Collected over AEs with onset from the date of enrollment up to 30 days after the last dose of study drug administration; assessed up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cetuximab—17/70 (24.3%)69/70 (98.6%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCetuximab
CholestaticjaundiceHepatobiliary disorders1/70
Acute cholecystitisHepatobiliary disorders1/70
CholangitisHepatobiliary disorders1/70
Liver failureHepatobiliary disorders1/70
PyrexiaGeneral disorders1/70
PainGeneral disorders1/70
General malaiseGeneral disorders1/70
Catheter point infectionInfections and infestations1/70
Listeria meningitisInfections and infestations1/70
Urinary tract infectionInfections and infestations1/70
Most frequent other events
Showing 10 of 30
Most frequent other events
EventCetuximab
RashSkin and subcutaneous tissue disorders39/70
AstheniaGeneral disorders32/70
Decreased appetiteMetabolism and nutrition disorders16/70
ConstipationGastrointestinal disorders15/70
NauseaGastrointestinal disorders12/70
VomitingGastrointestinal disorders11/70
Mucosal inflammationGeneral disorders10/70
PyrexiaGeneral disorders10/70
Back painMusculoskeletal and connective tissue disorders10/70
Abdominal painGastrointestinal disorders9/70

Baseline characteristics

MITT analysis set included all the subjects who received study drug treatment.

Age, Continuous
Age, Continuous(Years)Cetuximab
Mean63.61 ± 10.54
Sex: Female, Male
Sex: Female, Male(Participants)Cetuximab
Female34
Male36
08

Study locations

9 sites
  • Research Site
    A Coruña, Spain
  • Research Site
    Asturias, Spain
  • Research Site
    Barcelona, Spain
  • Research Site
    Cordoba, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Navarra, Spain
  • Research Site
    Santiago de Compostela, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Valencia, Spain
09

References and documents

Publications

  • Manzanares-Martin B, Cebrian Aranda A, Del Puerto-Nevado L, Gonzalez R, Solanes S, Gomez-Espana MA, Garcia-Foncillas J, Aranda E. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. J Immunother Cancer. 2021 Apr;9(4):e001705. doi: 10.1136/jitc-2020-001705. PubMed 33833048 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2011
First posted
Oct 12, 2011
Start
Dec 2011
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jun 15, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01450319
Collaborators
Merck, S.L., Spain
Responsible party
Sponsor
First posted
Oct 12, 2011
Start date
Dec 2011
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jun 15, 2016
Last update
Nov 28, 2016

Study contacts

Medical Director
study director · Merck, S.L., Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion